• Consensus Rating: Hold
  • Consensus Price Target: $19.44
  • Forecasted Upside: 22.87%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$15.82
▼ -0.76 (-4.58%)

This chart shows the closing price for CERT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Certara Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERT

Analyst Price Target is $19.44
▲ +22.87% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Certara in the last 3 months. The average price target is $19.44, with a high forecast of $24.00 and a low forecast of $15.50. The average price target represents a 22.87% upside from the last price of $15.82.

This chart shows the closing price for CERT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Certara. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/11/2024KeyCorpLower TargetOverweight ➝ Overweight$23.00 ➝ $20.00Low
7/10/2024JMP SecuritiesReiterated RatingMarket PerformLow
6/28/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$18.00 ➝ $16.00Low
4/10/2024KeyCorpUpgradeSector Weight ➝ Overweight$23.00Low
4/4/2024JMP SecuritiesInitiated CoverageMarket PerformLow
3/1/2024UBS GroupBoost TargetNeutral ➝ Neutral$17.00 ➝ $20.00Low
3/1/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$14.00 ➝ $15.50Low
2/26/2024Leerink PartnrsReiterated RatingMarket PerformLow
2/26/2024SVB LeerinkInitiated CoverageMarket Perform$19.00Low
1/25/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $18.00Low
12/7/2023UBS GroupInitiated CoverageNeutral$17.00Low
12/5/2023KeyCorpInitiated CoverageSector WeightLow
10/11/2023StephensReiterated RatingOverweight ➝ Overweight$20.00Low
8/22/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$24.50 ➝ $17.00Low
8/15/2023Bank of AmericaLower TargetBuy ➝ Buy$27.00 ➝ $24.00Low
8/11/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$18.00 ➝ $16.00Low
8/10/2023Credit Suisse GroupLower TargetOutperform ➝ Outperform$27.00 ➝ $21.00Low
8/10/2023William BlairDowngradeOutperform ➝ Market PerformLow
6/27/2023BarclaysLower Target$25.00 ➝ $18.00Low
4/11/2023StephensInitiated CoverageOverweight$28.00Low
4/3/2023BarclaysDowngradeOverweight ➝ Equal Weight$21.00 ➝ $25.00Low
3/27/2023Credit Suisse GroupBoost Target$22.00 ➝ $27.00Low
3/10/2023Morgan StanleyBoost TargetEqual Weight$20.00 ➝ $21.00Low
3/2/2023Credit Suisse GroupBoost TargetOutperform$20.00 ➝ $22.00Low
3/2/2023BarclaysBoost TargetOverweight$20.00 ➝ $21.00Low
1/24/2023BarclaysBoost TargetOverweight$17.00 ➝ $20.00Low
12/14/2022Robert W. BairdDowngradeOutperform ➝ Neutral$17.00 ➝ $19.00Low
11/14/2022Credit Suisse GroupLower TargetOutperform$22.00 ➝ $20.00Low
10/6/2022BarclaysLower TargetOverweight$21.00 ➝ $17.00Low
9/8/2022Berenberg BankInitiated CoverageBuy$23.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$22.00Low
8/24/2022Morgan StanleyLower TargetEqual Weight$24.00 ➝ $20.00Low
8/17/2022BarclaysLower TargetOverweight$24.00 ➝ $21.00Low
8/10/2022SVB LeerinkLower TargetOutperform$29.00 ➝ $26.00Low
8/10/2022Piper SandlerLower TargetOverweight$28.00 ➝ $25.00Low
7/15/2022SVB LeerinkInitiated CoverageOutperform$29.00Low
7/13/2022BarclaysLower TargetOverweight$25.00 ➝ $24.00N/A
7/1/2022Piper SandlerInitiated CoverageOverweight$28.00Low
3/3/2022Morgan StanleyLower TargetEqual Weight$27.00 ➝ $25.00High
3/3/2022BarclaysLower TargetOverweight$48.00 ➝ $26.00High
1/11/2022Jefferies Financial GroupUpgradeHold ➝ Buy$31.00High
9/17/2021Robert W. BairdBoost TargetOutperform$32.00 ➝ $41.00High
7/23/2021Robert W. BairdInitiated CoverageOutperform$30.00Medium
5/7/2021BarclaysLower TargetOverweight$40.00 ➝ $35.00Medium
3/8/2021Morgan StanleyLower TargetEqual Weight$35.00 ➝ $33.00High
3/5/2021William BlairReiterated RatingOutperformHigh
3/2/2021BarclaysInitiated CoverageOverweight$40.00High
1/5/2021Morgan StanleyInitiated CoverageEqual Weight$35.00N/A
1/5/2021Jefferies Financial GroupInitiated CoverageHold$33.00N/A
1/5/2021Credit Suisse GroupInitiated CoverageNeutral$35.00N/A
1/5/2021William BlairInitiated CoverageOutperformN/A
1/5/2021Bank of AmericaInitiated CoverageBuy$41.00N/A
(Data available from 7/23/2019 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/25/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 11 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/25/2024
  • 12 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024
  • 5 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/24/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/23/2024

Current Sentiment

  • 10 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Certara logo
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $15.82
Low: $15.82
High: $16.54

50 Day Range

MA: $15.39
Low: $13.36
High: $17.38

52 Week Range

Now: $15.82
Low: $11.81
High: $19.87

Volume

920,116 shs

Average Volume

568,354 shs

Market Capitalization

$2.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Certara?

The following Wall Street sell-side analysts have issued stock ratings on Certara in the last year: Bank of America Co., Barclays PLC, Credit Suisse Group AG, Jefferies Financial Group Inc., JMP Securities, KeyCorp, Leerink Partnrs, Stephens, SVB Leerink LLC, UBS Group AG, and William Blair.
View the latest analyst ratings for CERT.

What is the current price target for Certara?

8 Wall Street analysts have set twelve-month price targets for Certara in the last year. Their average twelve-month price target is $19.44, suggesting a possible upside of 22.9%. Bank of America Co. has the highest price target set, predicting CERT will reach $24.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $15.50 for Certara in the next year.
View the latest price targets for CERT.

What is the current consensus analyst rating for Certara?

Certara currently has 7 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CERT, but not buy more shares or sell existing shares.
View the latest ratings for CERT.

What other companies compete with Certara?

How do I contact Certara's investor relations team?

Certara's physical mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The company's listed phone number is 609-716-7900 and its investor relations email address is [email protected]. The official website for Certara is www.certara.com. Learn More about contacing Certara investor relations.